For several decades, few substantial therapeutic advances have been made for patients
with acute myeloid leukaemia. However, since 2017 unprecedented growth has been seen …

Progress in acute myeloid leukaemia treatment is occurring at an unprecedented pace. The
past decade has witnessed an increasingly improved scientific understanding of the …

Research has resulted in regulatory approval of nine agents for acute myeloid leukaemia
indications by the US Food and Drug Administration since 2017: the Bcl-2 inhibitor …

Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …

Acute myeloid leukemia (AML) is the most common acute leukemia in adults, with an
incidence of over 20 000 cases per year in the United States alone. Large chromosomal …

Acute myeloid leukemia (AML) is a heterogeneous disease. Until recently, treatment for
patients with AML was limited to induction chemotherapy with cytarabine and anthracycline …

Abstract Purpose of Review Awareness of the molecular landscape of AML has improved
AML care over the last 5 years. This review summarizes updates regarding the diagnostic …

In the past few years research in the underlying pathogenic mechanisms of acute myeloid
leukaemia (AML) has led to remarkable advances in our understanding of the disease …

Outcome in patients with acute myeloid leukemia (AML) ranges from death within a few days
of beginning treatment (treatment related mortality, TRM) to likely cure. The major reason …

Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults, with an
incidence that increases with age, and a generally poor prognosis. The disease is clinically …